62 related articles for article (PubMed ID: 22221142)
1. JAK3, STAT3 and CD3-zeta signaling proteins status in regard to the lymphocytes function in patients with ovarian cancer.
Klink M; Kielbik M; Nowak M; Bednarska K; Sulowska Z
Immunol Invest; 2012; 41(4):382-98. PubMed ID: 22221142
[TBL] [Abstract][Full Text] [Related]
2. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.
Kono K; Ressing ME; Brandt RM; Melief CJ; Potkul RK; Andersson B; Petersson M; Kast WM; Kiessling R
Clin Cancer Res; 1996 Nov; 2(11):1825-8. PubMed ID: 9816136
[TBL] [Abstract][Full Text] [Related]
4. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.
Nambiar MP; Fisher CU; Warke VG; Krishnan S; Mitchell JP; Delaney N; Tsokos GC
Arthritis Rheum; 2003 Jul; 48(7):1948-55. PubMed ID: 12847689
[TBL] [Abstract][Full Text] [Related]
6. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling.
Akyol S; Gercel-Taylor C; Reynolds LC; Taylor DD
Gynecol Oncol; 2006 Jun; 101(3):481-6. PubMed ID: 16386781
[TBL] [Abstract][Full Text] [Related]
7. Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjögren's syndrome.
Ramos HL; Valencia-Pacheco G; Alcocer-Varela J
Scand J Rheumatol; 2008; 37(1):35-9. PubMed ID: 18189193
[TBL] [Abstract][Full Text] [Related]
8. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors.
Taylor DD; Gerçel-Taylor C; Lyons KS; Stanson J; Whiteside TL
Clin Cancer Res; 2003 Nov; 9(14):5113-9. PubMed ID: 14613988
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
Rabinowich H; Reichert TE; Kashii Y; Gastman BR; Bell MC; Whiteside TL
J Clin Invest; 1998 Jun; 101(11):2579-88. PubMed ID: 9616229
[TBL] [Abstract][Full Text] [Related]
10. CD3 zeta expression of regional lymph node and peripheral blood lymphocytes in gastric cancer.
Ishigami S; Natsugoe S; Miyazono F; Tokuda K; Nakajo A; Matsumoto M; Okumura H; Nakashima S; Hokita S; Maruyama I; Aikou T
Anticancer Res; 2004; 24(3b):2123-6. PubMed ID: 15274412
[TBL] [Abstract][Full Text] [Related]
11. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
13. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients.
Taylor DD; Edwards RP; Case CR; Gerçel-Taylor C
Gynecol Oncol; 2004 Jul; 94(1):54-60. PubMed ID: 15262119
[TBL] [Abstract][Full Text] [Related]
14. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
15. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
16. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.
Taylor DD; Bender DP; Gerçel-Taylor C ; Stanson J; Whiteside TL
Br J Cancer; 2001 Jun; 84(12):1624-9. PubMed ID: 11401315
[TBL] [Abstract][Full Text] [Related]
17. Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff W; Voss M; Freichel S; Schmid A; Vogel I; Jöhnk C; Henne-Bruns D; Kremer B; Kalthoff H
Clin Cancer Res; 2001 Mar; 7(3 Suppl):925s-932s. PubMed ID: 11300493
[TBL] [Abstract][Full Text] [Related]
18. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
19. Alterations in signal transducing molecule CD3 zeta in patients with neoplastic diseases.
Frydecka I; Kaczmarek P; Boćko D; Kosmaczewska A; Ciszak L
Arch Immunol Ther Exp (Warsz); 1998; 46(6):355-9. PubMed ID: 9883314
[TBL] [Abstract][Full Text] [Related]
20. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
